Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 17/20 | 0.65 |
| ▸ | SLC5A1 | P13866 | 15/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574077 | 0.87 | SLC5A2 (0.74) | SLC5A2SLC5A1ACHE | |
| SCHEMBL4000120 | 0.84 | SLC5A2 (0.64) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4000126 | 0.84 | SLC5A2 (0.64) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL28713870 | 0.82 | SLC5A2 (0.74) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL2575031 | 0.82 | SLC5A2 (0.74) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL2577173 | 0.81 | SLC5A2 (0.79) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL2573609 | 0.80 | SLC5A2 (0.74) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL2578940 | 0.80 | SLC5A2 (0.70) | SLC5A2SLC5A1ACHENPC1RAB9A | |
| SCHEMBL4359584 | 0.79 | SLC5A2 (0.68) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4359089 | 0.79 | SLC5A2 (0.68) | SLC5A2SLC5A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC5A2 10/4885SLC5A1 12/4885ACHE 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.